Abstract
Hypertension is associated with an increase in cardiovascular events. Pathophysiological mechanisms of this include endothelial damage / dysfunction, inflammatory activation, insulin resistance, platelet activation and alterations in the coagulation cascade leading to a prothrombotic state. Dyslipidaemia acts synergistically with hypertension in increasing cardiovascular risk. HMG CoA reductase inhibitors (statins) are lipid-lowering drugs and more recently have been shown to have a significant pleiotropic effect on endothelial function, inflammation, platelet activation and coagulation. Statins affect the whole pathophysiology of atherogenesis from deposition to plaque rupture and thrombogenesis because of its pleiotropic effects. Therefore it is intuitive that statins may be of benefit in hypertensive patients with conventionally normal lipid levels by preventing the pathological effects of hypertension. There is an increasing clinical evidence base for statins use in patients with hypertension. In this article, the novel pleiotropic and conventional mechanisms of statins, and clinical data of statin therapy in patients with hypertension are reviewed.
Keywords: Endothelial dysfunction, platelets, Hypercholesterolemia, pleiotropic effect, dyslipidemia, lipoprotein, HMG CoA reductase
Current Pharmaceutical Design
Title: Novel Concepts of Statin Therapy for Cardiovascular Risk Reduction in Hypertension
Volume: 12 Issue: 13
Author(s): George I. Varughese, Jeetesh V. Patel, Gregory Y.H. Lip and Chetan Varma
Affiliation:
Keywords: Endothelial dysfunction, platelets, Hypercholesterolemia, pleiotropic effect, dyslipidemia, lipoprotein, HMG CoA reductase
Abstract: Hypertension is associated with an increase in cardiovascular events. Pathophysiological mechanisms of this include endothelial damage / dysfunction, inflammatory activation, insulin resistance, platelet activation and alterations in the coagulation cascade leading to a prothrombotic state. Dyslipidaemia acts synergistically with hypertension in increasing cardiovascular risk. HMG CoA reductase inhibitors (statins) are lipid-lowering drugs and more recently have been shown to have a significant pleiotropic effect on endothelial function, inflammation, platelet activation and coagulation. Statins affect the whole pathophysiology of atherogenesis from deposition to plaque rupture and thrombogenesis because of its pleiotropic effects. Therefore it is intuitive that statins may be of benefit in hypertensive patients with conventionally normal lipid levels by preventing the pathological effects of hypertension. There is an increasing clinical evidence base for statins use in patients with hypertension. In this article, the novel pleiotropic and conventional mechanisms of statins, and clinical data of statin therapy in patients with hypertension are reviewed.
Export Options
About this article
Cite this article as:
Varughese I. George, Patel V. Jeetesh, Lip Y.H. Gregory and Varma Chetan, Novel Concepts of Statin Therapy for Cardiovascular Risk Reduction in Hypertension, Current Pharmaceutical Design 2006; 12 (13) . https://dx.doi.org/10.2174/138161206776843304
DOI https://dx.doi.org/10.2174/138161206776843304 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies to Tackle Early Low Flow States in the Extremely Preterm Infant
Current Pediatric Reviews The Pathophysiology of Sleep Apnoea: What We have Learned from Animal Models of Chronic Intermittent Hypoxia
Current Respiratory Medicine Reviews Low 25 Hydroxyvitamin D Levels are Independently Associated with Autoimmune Thyroiditis in a Cohort of Apparently Healthy Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Adipocytokines in Non-functional Adrenal Incidentalomas and Relation with Insulin Resistance Parameters
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
Current Medicinal Chemistry Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews Nutrition Transition and Obesity Among Teenagers and Young Adults in South Asia
Current Diabetes Reviews Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Current Cardiology Reviews Noncoding RNAs and Intracerebral Hemorrhage
CNS & Neurological Disorders - Drug Targets Emerging Immunosuppressive Drugs in Kidney Transplantation
Current Clinical Pharmacology Mechanisms of Vascular Calcification and Associated Diseases
Current Pharmaceutical Design Neonatal Systemic Thrombosis: An Updated Overview
Current Vascular Pharmacology The Role of Diabetes Mellitus in Sexual and Reproductive Health: An Overview of Pathogenesis, Evaluation, and Management
Current Diabetes Reviews Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease
Current Enzyme Inhibition Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied
Recent Patents on Anti-Cancer Drug Discovery Insulin Resistance and Alzheimers Disease Pathogenesis: Potential Mechanisms and Implications for Treatment
Current Alzheimer Research